{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-022375","form_type":"8-K","ticker":"INSM","cik":"0001104506","company_name":"INSMED Inc","filed_at":"2025-06-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.532982+00:00","generated_at":"2026-05-19T07:34:01.963939+00:00","sec_items":["8.01","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Insmed prices $750M common stock offering at $96/share for brensocatib R&D and commercialization","bullets":["Priced 7,812,500 shares at $96.00; net proceeds ~$716.3M after underwriting discounts.","Underwriters granted 30-day option for up to 1,171,875 additional shares (~$112.5M).","Proceeds to fund brensocatib R&D, pre-commercial/commercial, ARIKAYCE, TPIP, INS1201, and general corporate.","Offering expected to close June 13, 2025; joint book-runners: Goldman Sachs, Leerink, BofA, Jefferies, J.P. Morgan."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-022375","json":"https://secwatch.observer/filing/0001140361-25-022375.json","markdown":"https://secwatch.observer/filing/0001140361-25-022375.md","text":"https://secwatch.observer/filing/0001140361-25-022375.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1104506/000114036125022375/0001140361-25-022375-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1104506/000114036125022375/ny20050461x3_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T07:34:01.963939+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}